IL287116A - Tricyclic joints of ikaros and aiolos - Google Patents
Tricyclic joints of ikaros and aiolosInfo
- Publication number
- IL287116A IL287116A IL287116A IL28711621A IL287116A IL 287116 A IL287116 A IL 287116A IL 287116 A IL287116 A IL 287116A IL 28711621 A IL28711621 A IL 28711621A IL 287116 A IL287116 A IL 287116A
- Authority
- IL
- Israel
- Prior art keywords
- aiolos
- ikaros
- degraders
- tricyclic
- tricyclic degraders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833107P | 2019-04-12 | 2019-04-12 | |
| PCT/US2020/027678 WO2020210630A1 (en) | 2019-04-12 | 2020-04-10 | Tricyclic degraders of ikaros and aiolos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL287116A true IL287116A (en) | 2021-12-01 |
Family
ID=72750851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL287116A IL287116A (en) | 2019-04-12 | 2021-10-10 | Tricyclic joints of ikaros and aiolos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11407732B1 (ru) |
| EP (1) | EP3953332A4 (ru) |
| JP (1) | JP2022527216A (ru) |
| KR (1) | KR20210152515A (ru) |
| CN (1) | CN113677664A (ru) |
| AU (1) | AU2020272978A1 (ru) |
| BR (1) | BR112021019669A2 (ru) |
| CA (1) | CA3130469A1 (ru) |
| EA (1) | EA202192738A1 (ru) |
| IL (1) | IL287116A (ru) |
| MA (1) | MA55628A (ru) |
| MX (1) | MX2021012524A (ru) |
| SG (1) | SG11202109024YA (ru) |
| WO (1) | WO2020210630A1 (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019043214A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | glutarimide |
| EP3848371A4 (en) * | 2018-09-07 | 2022-06-08 | Medshine Discovery Inc. | TRICYCLIC FURAN-SUBSTITUTED PIPERIDONEE COMPOUND |
| AU2020405237A1 (en) | 2019-12-20 | 2022-07-07 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of EGFR |
| US11807620B2 (en) | 2020-02-21 | 2023-11-07 | Plexium, Inc. | Quinazolinone compounds and related compounds |
| TW202220981A (zh) * | 2020-08-07 | 2022-06-01 | 美商Ｃ４醫藥公司 | 用於伊卡洛斯(ikaros)或愛露斯(aiolos)介導之病症之有利療法 |
| MX2023004374A (es) * | 2020-10-14 | 2023-07-06 | C4 Therapeutics Inc | Ligandos tricíclicos para la degradación de la familia ikaros 2 o la familia ikaros 4. |
| KR20230107570A (ko) * | 2020-10-14 | 2023-07-17 | 씨4 테라퓨틱스, 인코포레이티드 | 표적화 단백질의 분해를 위한 트리시클릭 이종이관능성 화합물 |
| MX2023013046A (es) | 2021-05-05 | 2023-12-15 | Biogen Ma Inc | Compuestos para direccionar la degradacion de tirosina cinasa de bruton. |
| WO2023283130A1 (en) | 2021-07-04 | 2023-01-12 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
| JP2024525580A (ja) | 2021-07-07 | 2024-07-12 | バイオジェン・エムエイ・インコーポレイテッド | Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 |
| UY39844A (es) | 2021-07-07 | 2023-01-31 | Biogen Ma Inc | Compuestos para la degradación selectiva de las proteínas irak4 |
| WO2023025112A1 (zh) * | 2021-08-27 | 2023-03-02 | 杭州格博生物医药有限公司 | 异吲哚啉酮化合物及其用途 |
| WO2023059792A1 (en) * | 2021-10-06 | 2023-04-13 | C4 Thrapeutics, Inc. | Coronavirus non-structural protein 3 degrading compounds |
| WO2023061478A1 (zh) * | 2021-10-15 | 2023-04-20 | 先声再明医药有限公司 | 三环类化合物 |
| WO2023154417A1 (en) * | 2022-02-09 | 2023-08-17 | C4 Therapeutics, Inc. | Morphic forms of cft7455 and methods of manufacture thereof |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| CN116120261B (zh) * | 2022-11-30 | 2024-01-23 | 浙大宁波理工学院 | 一种3-[（4-磺胺哌嗪-1-基）甲基]苯甲酸类化合物的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6504034B2 (en) * | 2001-01-23 | 2003-01-07 | Hoffmann-La Roche Inc. | Naphthostyrils |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| CL2007002513A1 (es) | 2006-08-30 | 2008-04-04 | Celgene Corp Soc Organizada Ba | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. |
| CN103382197A (zh) | 2006-09-15 | 2013-11-06 | 细胞基因公司 | N-甲基氨甲基异吲哚化合物和包含它的组合物及其使用方法 |
| PL2428513T3 (pl) | 2006-09-26 | 2017-10-31 | Celgene Corp | Pochodne 5-podstawionego chinazolinonu jako środki przeciwnowotworowe |
| NZ579890A (en) | 2007-03-20 | 2012-05-25 | Celgene Corp | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| EP2200999B1 (en) | 2007-09-26 | 2014-08-13 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
| WO2009139880A1 (en) | 2008-05-13 | 2009-11-19 | Celgene Corporation | Thioxoisoindoline compounds and compositions and methods of using the same |
| EP3354646A1 (en) | 2008-10-29 | 2018-08-01 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| WO2012175481A1 (en) | 2011-06-20 | 2012-12-27 | Institut Curie | Compositions and methods for treating leukemia |
| EP2802608A4 (en) | 2012-01-12 | 2015-08-05 | Univ Yale | COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY E3 UBIQUITIN LIGASE |
| CA3206268A1 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| CN111662226B (zh) * | 2015-01-28 | 2022-03-18 | 中国科学院广州生物医药与健康研究院 | 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物 |
| PL3404024T3 (pl) | 2016-01-14 | 2021-04-19 | Kangpu Biopharmaceuticals, Ltd. | Pochodna chinazolinonu, sposób jej przygotowania, kompozycja farmaceutyczna i zastosowania |
| WO2017197056A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| PL3527210T3 (pl) | 2016-12-16 | 2021-11-29 | Kangpu Biopharmaceuticals, Ltd. | Kombinacja skojarzona zawierająca związek benzoheterocykliczny i modulator szlaku receptora androgenowego oraz jej zastosowania |
| RU2733950C1 (ru) | 2017-02-13 | 2020-10-08 | Канпу Биофармасьютикалс, Лтд. | Комбинация для лечения рака предстательной железы, фармацевтическая композиция и способ лечения |
| US11337964B2 (en) | 2017-02-28 | 2022-05-24 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, pharmaceutical composition and use thereof |
| JP7258009B2 (ja) | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| US10905684B2 (en) | 2018-06-13 | 2021-02-02 | Biotheryx, Inc. | Aminoamide compounds |
| CN113166100A (zh) | 2018-06-29 | 2021-07-23 | 达纳-法伯癌症研究所有限公司 | 免疫调节性化合物 |
| US12030892B2 (en) | 2018-06-29 | 2024-07-09 | Dana-Farber Cancer Institute, Inc. | CRBN modulators |
| AU2019294836B2 (en) | 2018-06-29 | 2024-06-20 | Dana-Farber Cancer Institute, Inc. | Bispecific degraders |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| LT3820573T (lt) | 2018-07-10 | 2023-11-10 | Novartis Ag | 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-diono dariniai ir jų naudojimas gydyti nuo ikaros šeimos cinko pirštų 2 (ikzf2) priklausomas ligas |
| CA3151824A1 (en) | 2019-08-27 | 2021-03-04 | The Regents Of The University Of Michigan | Cereblon e3 ligase inhibitors |
| WO2021127586A1 (en) | 2019-12-20 | 2021-06-24 | Calico Life Sciences Llc | Protein tyrosine phosphatase degraders and methods of use thereof |
-
2020
- 2020-04-10 EA EA202192738A patent/EA202192738A1/ru unknown
- 2020-04-10 CN CN202080028010.XA patent/CN113677664A/zh active Pending
- 2020-04-10 MX MX2021012524A patent/MX2021012524A/es unknown
- 2020-04-10 KR KR1020217036582A patent/KR20210152515A/ko unknown
- 2020-04-10 AU AU2020272978A patent/AU2020272978A1/en active Pending
- 2020-04-10 CA CA3130469A patent/CA3130469A1/en active Pending
- 2020-04-10 SG SG11202109024YA patent/SG11202109024YA/en unknown
- 2020-04-10 WO PCT/US2020/027678 patent/WO2020210630A1/en active Application Filing
- 2020-04-10 BR BR112021019669A patent/BR112021019669A2/pt unknown
- 2020-04-10 JP JP2021559999A patent/JP2022527216A/ja active Pending
- 2020-04-10 EP EP20788335.6A patent/EP3953332A4/en active Pending
- 2020-04-10 MA MA055628A patent/MA55628A/fr unknown
-
2021
- 2021-10-10 IL IL287116A patent/IL287116A/en unknown
- 2021-10-11 US US17/498,617 patent/US11407732B1/en active Active
-
2022
- 2022-04-18 US US17/723,199 patent/US20230082430A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202109024YA (en) | 2021-09-29 |
| JP2022527216A (ja) | 2022-05-31 |
| AU2020272978A1 (en) | 2021-09-16 |
| CN113677664A (zh) | 2021-11-19 |
| EP3953332A1 (en) | 2022-02-16 |
| US20230082430A1 (en) | 2023-03-16 |
| WO2020210630A1 (en) | 2020-10-15 |
| BR112021019669A2 (pt) | 2021-12-07 |
| MA55628A (fr) | 2022-02-16 |
| CA3130469A1 (en) | 2020-10-15 |
| EP3953332A4 (en) | 2023-06-14 |
| MX2021012524A (es) | 2021-11-12 |
| EA202192738A1 (ru) | 2022-03-17 |
| US11407732B1 (en) | 2022-08-09 |
| KR20210152515A (ko) | 2021-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287116A (en) | Tricyclic joints of ikaros and aiolos | |
| IL283471A (en) | Iraq joints and their uses | |
| IL276731A (en) | Antibodies against CD73 and methods of using them | |
| IL277729A (en) | modulators of proteolysis and related methods of use | |
| IL278821A (en) | Anti-SIRPA antibodies and methods of using them | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| IL289813A (en) | Antibody against tau and its use | |
| IL275734B (en) | Anti-pd-l1 antibodies and uses thereof | |
| IL268112A (en) | Anti-TGF-beta antibodies and their use | |
| IL270214A (en) | Anti-sortilin antibodies and methods of using them | |
| KR102116512B9 (ko) | 무색 투명한 폴리아마이드-이미드 필름 및 이의 제조방법 | |
| SG11202106498XA (en) | Anti-ctla4 antibodies and methods of use thereof | |
| IL277212A (en) | Anti-KLK5 antibodies and methods of use | |
| IL279648A (en) | Anti-SIRP-in-cell 1 antibodies and methods of using them | |
| IL287282A (en) | Anti-mertk antibodies and methods of using them | |
| IL290741A (en) | Antibodies against cd-96 and methods of using them | |
| SG11202108734VA (en) | Anti-trem2 antibodies and methods of use thereof | |
| EP3803976C0 (en) | LED DISPLAY STRUCTURES AND THEIR MANUFACTURING | |
| IL289952A (en) | Anti-ms4a4a antibodies and methods of using them | |
| IL285401A (en) | Anti-clec2d antibodies and methods of using them | |
| IL283884A (en) | Antibodies against il-36 and methods of using them | |
| IL280338A (en) | Anti-SIGLEC-5 antibodies and methods of using them | |
| IL291461A (en) | Anti-alpha-synuclein antibodies and methods of using them | |
| IL288886A (en) | Antibodies and methods of use | |
| IL279227A (en) | Anti-SIGLEC-7 antibodies and methods of using them |